MX368474B - Uso de benralizumab para mejorar síntomas de asma. - Google Patents

Uso de benralizumab para mejorar síntomas de asma.

Info

Publication number
MX368474B
MX368474B MX2016001195A MX2016001195A MX368474B MX 368474 B MX368474 B MX 368474B MX 2016001195 A MX2016001195 A MX 2016001195A MX 2016001195 A MX2016001195 A MX 2016001195A MX 368474 B MX368474 B MX 368474B
Authority
MX
Mexico
Prior art keywords
benralizumab
methods
asthma symptoms
improving asthma
improving
Prior art date
Application number
MX2016001195A
Other languages
English (en)
Other versions
MX2016001195A (es
Inventor
Wang Bing
Roskos Lorin
Ward Christine
Raible Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016001195A publication Critical patent/MX2016001195A/es
Publication of MX368474B publication Critical patent/MX368474B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de benralizumab en la preparación de un medicamento para mejorar la puntuación del cuestionario de asma en un paciente asmático, en donde el benralizumab o un fragmento de unión al antígeno de este está adaptado para ser administrable al paciente, en donde el benralizumab o fragmento de unión al antígeno es administrable en 30 mg por dosis.
MX2016001195A 2013-08-12 2014-08-07 Uso de benralizumab para mejorar síntomas de asma. MX368474B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
PCT/US2014/050122 WO2015023508A2 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (2)

Publication Number Publication Date
MX2016001195A MX2016001195A (es) 2016-07-21
MX368474B true MX368474B (es) 2019-10-04

Family

ID=52448839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001195A MX368474B (es) 2013-08-12 2014-08-07 Uso de benralizumab para mejorar síntomas de asma.

Country Status (18)

Country Link
US (1) US9441047B2 (es)
EP (3) EP3536339B1 (es)
JP (2) JP6803229B2 (es)
KR (1) KR102337601B1 (es)
CN (2) CN105451761A (es)
AU (3) AU2014306960B2 (es)
BR (1) BR112016002462A8 (es)
CA (1) CA2918050C (es)
DK (2) DK3033103T3 (es)
ES (2) ES2740355T3 (es)
HK (1) HK1221647A1 (es)
HU (2) HUE045402T2 (es)
MX (1) MX368474B (es)
PL (2) PL3033103T3 (es)
RU (1) RU2728578C2 (es)
SG (1) SG11201600484TA (es)
TR (1) TR201910413T4 (es)
WO (1) WO2015023508A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
CN105451760A (zh) 2013-08-12 2016-03-30 米迪缪尼有限公司 使用贝那利珠单抗降低哮喘恶化率的方法
EP3485902A1 (en) * 2013-10-15 2019-05-22 Astrazeneca AB Methods for treating chronic obstructive pulmonary disease using benralizumab
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk ANTIBODY COMPOSITION SPECIFICALLY BINDING TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
ES2558689T3 (es) * 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
WO2012083132A2 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
CA2853858A1 (en) 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
CN105451760A (zh) 2013-08-12 2016-03-30 米迪缪尼有限公司 使用贝那利珠单抗降低哮喘恶化率的方法

Also Published As

Publication number Publication date
EP3536339A1 (en) 2019-09-11
RU2020123894A (ru) 2020-09-18
AU2020202564A1 (en) 2020-05-07
BR112016002462A8 (pt) 2018-06-12
CA2918050C (en) 2023-10-03
KR20160042123A (ko) 2016-04-18
EP3536339B1 (en) 2021-10-06
BR112016002462A2 (pt) 2017-09-12
EP3033103A4 (en) 2017-03-22
MX2016001195A (es) 2016-07-21
HK1221647A1 (zh) 2017-06-09
HUE057065T2 (hu) 2022-04-28
US9441047B2 (en) 2016-09-13
EP3033103A2 (en) 2016-06-22
CN111617244A (zh) 2020-09-04
CA2918050A1 (en) 2015-02-19
PL3033103T3 (pl) 2019-10-31
PL3536339T3 (pl) 2022-02-21
WO2015023508A3 (en) 2015-04-16
WO2015023508A2 (en) 2015-02-19
DK3033103T3 (da) 2019-08-05
US20150044204A1 (en) 2015-02-12
ES2740355T3 (es) 2020-02-05
WO2015023508A8 (en) 2015-10-15
DK3536339T3 (da) 2021-12-20
AU2023214323A1 (en) 2023-10-19
JP2020100653A (ja) 2020-07-02
RU2728578C2 (ru) 2020-07-30
JP2016527326A (ja) 2016-09-08
EP3033103B1 (en) 2019-06-05
ES2901634T3 (es) 2022-03-23
EP3988114A1 (en) 2022-04-27
JP6803229B2 (ja) 2020-12-23
RU2016108734A (ru) 2017-09-19
AU2014306960B2 (en) 2020-01-16
HK1225303A1 (en) 2017-09-08
HUE045402T2 (hu) 2019-12-30
CN105451761A (zh) 2016-03-30
AU2014306960A1 (en) 2016-02-04
KR102337601B1 (ko) 2021-12-10
RU2016108734A3 (es) 2018-06-18
TR201910413T4 (tr) 2019-08-21
SG11201600484TA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
CY1122278T1 (el) Αντι il-36r αντισωματα
PH12014502406A1 (en) Anti-il-23p19 antibodies
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX381456B (es) Regulador de ph de transduccion.
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX2016009877A (es) Anticuerpos anti-baff novedosos.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
EA201491581A1 (ru) Везикулярные композиции
CL2017002304A1 (es) Métodos para tratar enfermedades
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
TN2014000207A1 (en) Anti il-36r antibodies
TN2013000114A1 (en) Methods and compositions for treating lung cancer
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ASTRAZENECA AB

FG Grant or registration